



Caladrius Biosciences to Present at Upcoming March Conferences

March 2, 2017



BASKING RIDGE, N.J., Mar. 2, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the Company’s leadership and experts will present at the following upcoming March conferences:

ISBiotech 7th Spring Meeting

- **Date and Time:** Tuesday, March 7, 2017, 9:15 AM ET
- **Website:** <http://www.isbiotech.org/cellulartherapies>
- **Venue:** Mead Center for American Theater, Washington, DC
- **Topic:** Successful Manufacturing of CAR T-Cell Therapies: Challenges and Opportunities
- **Presenter:** Cenk Sumen, PhD, Senior Manager, Business Development, PCT

29th Annual ROTH Conference

- **Date and Time:** Tuesday, March 14, 2017, 8:00 AM PT
- **Website:** <http://www.roth.com/main/page.aspx?PageID=7281>
- **Venue:** The Ritz Carlton, Dana Point, California
- **Presentation:** Company Presentation
- **Presenter:** David J. Mazzo, PhD, Chief Executive Officer, Caladrius
- **Webcast:** <https://www.caladrius.com//events>

9th Annual International Conference on NMO (neuromyelitis optica)

- **Date and Time:** Tuesday, March 14, 2017, 11:15 AM PT
- **Website:** <https://guthyjacksonfoundation.org/events/power-rare-9th-annual-international-conference-nmo/>
- **Venue:** Hilton LAX, Los Angeles, California
- **Presentation:** Autologous Treg Therapy is a Compelling Strategy for Treating NMOSD
- **Presenter:** Douglas Losordo, MD, Chief Medical Officer, Caladrius

7th Annual ARM Advanced Therapies Summit

- **Venue:** AC Hotel Barcelona Forum, Barcelona, Spain

Session 1

- **Date and Time:** Wednesday, March 22, 2017, 9:00 AM CET
- **Presentation:** Welcome and State of the Industry Remarks
- **Presenter:** Robert Preti, PhD, President, PCT and Chairman, Alliance for Regenerative Medicine

Session 2

- **Date and Time:** Wednesday, March 22, 2017, 3:30 PM CET
- **Panel:** Manufacturing, Industrialization and Infrastructure Roundtable
- **Panelist:** Robert Preti, PhD, President, PCT and Chairman, Alliance for Regenerative Medicine

8th Annual Life Science CEO Forum

- **Date and Time:** Thursday, March 23, 2017, 1:45 PM PT
- **Website:** <http://www.q1productions.com/ceoforum/day-one/>
- **Venue:** Renaissance San Diego Downtown, San Diego, California
- **Panel:** What Does Growth Mean to You?
- **Panelist:** David J. Mazzo, PhD, Chief Executive Officer, Caladrius

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The company's subsidiary, PCT, is a leading development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. For more information on Caladrius please visit www.caladrius.com and for more information on PCT please visit www.pctcaladrius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 15, 2016, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.



Source: Caladrius Biosciences, Inc.